Literature DB >> 34257452

Molecular and cellular basis of genetically inherited skeletal muscle disorders.

James J Dowling1,2, Conrad C Weihl3, Melissa J Spencer4.   

Abstract

Neuromuscular disorders comprise a diverse group of human inborn diseases that arise from defects in the structure and/or function of the muscle tissue - encompassing the muscle cells (myofibres) themselves and their extracellular matrix - or muscle fibre innervation. Since the identification in 1987 of the first genetic lesion associated with a neuromuscular disorder - mutations in dystrophin as an underlying cause of Duchenne muscular dystrophy - the field has made tremendous progress in understanding the genetic basis of these diseases, with pathogenic variants in more than 500 genes now identified as underlying causes of neuromuscular disorders. The subset of neuromuscular disorders that affect skeletal muscle are referred to as myopathies or muscular dystrophies, and are due to variants in genes encoding muscle proteins. Many of these proteins provide structural stability to the myofibres or function in regulating sarcolemmal integrity, whereas others are involved in protein turnover, intracellular trafficking, calcium handling and electrical excitability - processes that ensure myofibre resistance to stress and their primary activity in muscle contraction. In this Review, we discuss how defects in muscle proteins give rise to muscle dysfunction, and ultimately to disease, with a focus on pathologies that are most common, best understood and that provide the most insight into muscle biology.
© 2021. Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34257452     DOI: 10.1038/s41580-021-00389-z

Source DB:  PubMed          Journal:  Nat Rev Mol Cell Biol        ISSN: 1471-0072            Impact factor:   94.444


  262 in total

1.  Localization and cloning of Xp21 deletion breakpoints involved in muscular dystrophy.

Authors:  A P Monaco; C J Bertelson; C Colletti-Feener; L M Kunkel
Journal:  Hum Genet       Date:  1987-03       Impact factor: 4.132

2.  Dystrophin: the protein product of the Duchenne muscular dystrophy locus.

Authors:  E P Hoffman; R H Brown; L M Kunkel
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

Review 3.  Myotonic dystrophy: approach to therapy.

Authors:  Charles A Thornton; Eric Wang; Ellie M Carrell
Journal:  Curr Opin Genet Dev       Date:  2017-04-01       Impact factor: 5.578

Review 4.  Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment.

Authors:  Andrew G Engel; Xin-Ming Shen; Duygu Selcen; Steven M Sine
Journal:  Lancet Neurol       Date:  2015-04       Impact factor: 44.182

Review 5.  Emerging preclinical animal models for FSHD.

Authors:  Angela Lek; Fedik Rahimov; Peter L Jones; Louis M Kunkel
Journal:  Trends Mol Med       Date:  2015-03-20       Impact factor: 11.951

6.  Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle.

Authors:  J M Ervasti; K Ohlendieck; S D Kahl; M G Gaver; K P Campbell
Journal:  Nature       Date:  1990-05-24       Impact factor: 49.962

7.  Association of dystrophin and an integral membrane glycoprotein.

Authors:  K P Campbell; S D Kahl
Journal:  Nature       Date:  1989-03-16       Impact factor: 49.962

8.  Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene.

Authors:  A P Monaco; R L Neve; C Colletti-Feener; C J Bertelson; D M Kurnit; L M Kunkel
Journal:  Nature       Date:  1986 Oct 16-22       Impact factor: 49.962

Review 9.  Recent advances in understanding amyotrophic lateral sclerosis and emerging therapies.

Authors:  Lauren M Gittings; Rita Sattler
Journal:  Fac Rev       Date:  2020-11-17

10.  Meeting report: the 2020 FSHD International Research Congress.

Authors:  Michael Kyba; Robert J Bloch; Julie Dumonceaux; Scott Q Harper; Silvère M van der Maarel; Francis M Sverdrup; Kathryn R Wagner; Baziel van Engelen; Yi-Wen Chen
Journal:  Skelet Muscle       Date:  2020-12-08       Impact factor: 4.912

View more
  14 in total

Review 1.  Complexity of skeletal muscle degeneration: multi-systems pathophysiology and organ crosstalk in dystrophinopathy.

Authors:  Kay Ohlendieck; Dieter Swandulla
Journal:  Pflugers Arch       Date:  2021-09-22       Impact factor: 4.458

Review 2.  Centronuclear Myopathy Caused by Defective Membrane Remodelling of Dynamin 2 and BIN1 Variants.

Authors:  Kenshiro Fujise; Satoru Noguchi; Tetsuya Takeda
Journal:  Int J Mol Sci       Date:  2022-06-03       Impact factor: 6.208

Review 3.  Histopathology of Duchenne muscular dystrophy in correlation with changes in proteomic biomarkers.

Authors:  Margit Zweyer; Hemmen Sabir; Paul Dowling; Stephen Gargan; Sandra Murphy; Dieter Swandulla; Kay Ohlendieck
Journal:  Histol Histopathol       Date:  2021-12-07       Impact factor: 2.303

4.  Messenger RNA brings gene editing a step closer to treat muscular dystrophies.

Authors:  John Jacob
Journal:  Mol Ther Nucleic Acids       Date:  2022-04-21       Impact factor: 10.183

5.  BET1 variants establish impaired vesicular transport as a cause for muscular dystrophy with epilepsy.

Authors:  Sandra Donkervoort; Niklas Krause; Mykola Dergai; Pomi Yun; Judith Koliwer; Svetlana Gorokhova; Janelle Geist Hauserman; Beryl B Cummings; Ying Hu; Rosemarie Smith; Prech Uapinyoying; Vijay S Ganesh; Partha S Ghosh; Kristin G Monaghan; Seby L Edassery; Pia E Ferle; Sarah Silverstein; Katherine R Chao; Molly Snyder; Sara Ellingwood; Diana Bharucha-Goebel; Susan T Iannaccone; Matteo Dal Peraro; A Reghan Foley; Jeffrey N Savas; Véronique Bolduc; Dirk Fasshauer; Carsten G Bönnemann; Michael Schwake
Journal:  EMBO Mol Med       Date:  2021-11-15       Impact factor: 12.137

Review 6.  Rho GTPases in Skeletal Muscle Development and Homeostasis.

Authors:  Sonia Rodríguez-Fdez; Xosé R Bustelo
Journal:  Cells       Date:  2021-11-02       Impact factor: 6.600

7.  CRISPR/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy.

Authors:  Seraina A Domenig; Nicola Bundschuh; Ajda Lenardič; Adhideb Ghosh; Inseon Kim; Xhem Qabrati; Gommaar D'Hulst; Ori Bar-Nur
Journal:  Stem Cell Reports       Date:  2022-01-06       Impact factor: 7.294

8.  mRNA-mediated delivery of gene editing tools to human primary muscle stem cells.

Authors:  Christian Stadelmann; Silvia Di Francescantonio; Andreas Marg; Stefanie Müthel; Simone Spuler; Helena Escobar
Journal:  Mol Ther Nucleic Acids       Date:  2022-02-28       Impact factor: 8.886

9.  Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.

Authors:  Massimo Ganassi; Peter S Zammit
Journal:  Eur J Transl Myol       Date:  2022-03-18

10.  Characterization of a novel zebrafish model of SPEG-related centronuclear myopathy.

Authors:  Karla G Espinosa; Salma Geissah; Linda Groom; Jonathan Volpatti; Ian C Scott; Robert T Dirksen; Mo Zhao; James J Dowling
Journal:  Dis Model Mech       Date:  2022-05-09       Impact factor: 5.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.